Search

Roche Holding AG

Open

SectorHealthcare

294.8 -2.06

Overview

Share price change

24h

Current

Min

291

Max

302.2

Key metrics

By Trading Economics

Income

6.3B

Sales

31B

P/E

Sector Avg

29.748

63.778

Dividend yield

3.1

Profit margin

20.347

Employees

103,249

EBITDA

11B

Dividends

By Dow Jones

Dividend yield

Sector Avg

3.10%

2.39%

Market Stats

By TradingEconomics

Market Cap

233B

Previous open

296.86

Previous close

294.8

News Sentiment

By Acuity

48%

52%

176 / 386 Ranking in Healthcare

Roche Holding AG Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 mar 2025, 09:23 UTC

Major Market Movers

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

30 sty 2025, 09:36 UTC

Earnings

Roche Expects Growth to Continue This Year After Sales, Earnings Beat Forecasts -- Update

30 sty 2025, 06:32 UTC

Earnings

Roche Expects Sales, Earnings Growth After Better-Than-Expected Results

26 lis 2024, 15:27 UTC

Acquisitions, Mergers, Takeovers

Trending: Roche to Buy Poseida Therapeutics for Up to $1.5 Billion

31 mar 2025, 09:31 UTC

Hot Stocks

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

13 mar 2025, 07:46 UTC

Market Talk

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

12 mar 2025, 16:34 UTC

Top News

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 mar 2025, 08:51 UTC

Market Talk

Roche's Multiple-Sclerosis Drug Sales Potential Fuels Rating Upgrade -- Market Talk

12 mar 2025, 08:18 UTC

Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

13 lut 2025, 11:43 UTC

Market Talk

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

30 sty 2025, 07:56 UTC

Market Talk
Earnings

Roche Delivered Solid Results But Diagnostics' Profitability Disappoints -- Market Talk

30 sty 2025, 06:04 UTC

Earnings

Roche Expects 2025 EPS Growth in High Single Digit Range at Constant Currency

30 sty 2025, 06:04 UTC

Earnings

Roche Expects 2025 Sales Increase in Mid Single Digit Range at Constant Currency

30 sty 2025, 06:04 UTC

Earnings

Roche Issues 2025 View

30 sty 2025, 06:03 UTC

Earnings

Roche Raises Dividend to CHF9.70 Vs CHF9.60

30 sty 2025, 06:03 UTC

Earnings

Roche 2024 Core Operating Profit CHF20.82B

30 sty 2025, 06:03 UTC

Earnings

Roche 2024 Net Pft CHF9.19B

30 sty 2025, 06:02 UTC

Earnings

Analysts Saw 2024 Core EPS at CHF18.59

30 sty 2025, 06:02 UTC

Earnings

Roche 2024 Core EPS CHF18.80

30 sty 2025, 06:02 UTC

Earnings

Roche 2024 Sales EUR60.50B

30 sty 2025, 06:02 UTC

Earnings

Analysts Saw Roche 2024 Revenue at CHF60.41B

30 sty 2025, 06:01 UTC

Earnings

Roche 2024 Sales CHFB

28 sty 2025, 10:30 UTC

Top News

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

28 sty 2025, 07:24 UTC

Market Talk

Roche's Breast Cancer Drug Extends Life of Patients -- Market Talk

15 sty 2025, 10:22 UTC

Market Talk

Swiss Companies Pay Record Level of Dividends as Buybacks Fall -- Market Talk

8 sty 2025, 06:15 UTC

Acquisitions, Mergers, Takeovers

Roche: 66.11% of Poseida's Shares Were Validly Tendered in Offer

8 sty 2025, 06:12 UTC

Acquisitions, Mergers, Takeovers

Roche Intends to Complete Acquisition of Poseida Therapeutics Later Wednesday

16 gru 2024, 22:03 UTC

Top News

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13 gru 2024, 16:36 UTC

Market Talk

Swiss Equities an Overweight Pick Next Year -- Market Talk

26 lis 2024, 16:10 UTC

Acquisitions, Mergers, Takeovers

Why This Gene-Therapy Company's Stock Is Rising 228% -- Barrons.com

Roche Holding AG Forecast

Sentiment

By Acuity

176 / 386 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.